# OnCo record brian-rini (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/brian-rini/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "brian-rini" ;
  schema:name "Brian I. Rini"@en ;
  schema:description "Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer."@en ;
  schema:url <https://onco.cc/people/brian-rini/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Rini%20BI%5BAuthor%5D%20renal%20pembrolizumab%20axitinib> ;
  onco:tag "rcc", "immunotherapy", "trialist" ;
  schema:jobTitle "Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Cancer Research" ;
  schema:sameAs <https://orcid.org/0000-0002-2212-080X> ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:institutions <https://onco.cc/institutions/vanderbilt-ingram/> ;
  onco:trials <https://onco.cc/trials/keynote-426/> ;
  schema:affiliation <https://onco.cc/institutions/vanderbilt-ingram/> .